M. Stojanovic

18 papers receiving 1.0k citations

Hit Papers

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial 2012 · 883 citations
8830+4+9Years since publication250500750

Peers

M. Stojanovic
Comparison fields: 5 of 72
  • Pathology and Forensic Medicine 815
  • Neurology 361
  • Rheumatology 249
  • Immunology 241
  • Oncology 271
Replace Amy Pace with:
Amy Pace United States
Marianna Manfrini Switzerland
Pedro Oyuela United States
Aaron Miller United Kingdom
Tamara Miller United States
Karthinathan Thangavelu United States
Paul O’Connor Canada
Pierangelo Barbero Italy
Bella Ertik United States
Lisa Costelloe Ireland
M. Stojanovic relative to Amy Pace United States Amy Pace's profile →
Citations per field
00.5×2.7×
Amy Pace · 1×
Citations per year

Countries citing papers authored by M. Stojanovic

Since Specialization
Citations

This map shows the geographic impact of M. Stojanovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Stojanovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Stojanovic more than expected).

Fields of papers citing papers by M. Stojanovic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Stojanovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Stojanovic. The network helps show where M. Stojanovic may publish in the future.

Co-authors

The 25 scholars most cited alongside M. Stojanovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Stojanovic Line = papers co-authored together M. Stojanovic links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Hit paper breakdown →
2012883
2 201627
3 201726
4 201817
5 202010
6 19899
7 20207
8 20137
9 20136
10 20125
11 20135
12 20125
13 20184
14 20124
15 20123
16 20123
17 20122
18 20161

About M. Stojanovic

M. Stojanovic is a scholar working on Pathology and Forensic Medicine, Cellular and Molecular Neuroscience, Neurology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 18 papers that have together received 1.0k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (9 papers), Peripheral Neuropathies and Disorders (5 papers), Hereditary Neurological Disorders (4 papers), Immunotherapy and Immune Responses (4 papers), Peripheral Nerve Disorders (3 papers), Long-Term Effects of COVID-19 (2 papers), Acute Lymphoblastic Leukemia research (2 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). The work is most often cited by research in Pathology and Forensic Medicine (815 citations), Neurology (361 citations), Rheumatology (249 citations), Immunology (241 citations) and Oncology (271 citations). M. Stojanovic has collaborated with scholars based in Serbia, United Kingdom and Croatia. Frequent co-authors include Vesna Brinar, David Margolin, Krzysztof Selmaj, Douglas L. Arnold, Alasdair Coles, Stephen Lake, Gavin Giovannoni, Eva Havrdová, Jeffrey Cohen and Howard L. Weiner. Their work appears in journals such as Neurology, Journal of the Peripheral Nervous System, Journal of the Neurological Sciences, Journal of Neurology and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact